Search...
Key facts: Biogen's Alzheimer's drug delays progression by 30%; CEO boosts shares
I'm PortAI, I can summarize articles.
Biogen's Alzheimer's treatments, targeting amyloid deposits, have shown a 30% delay in disease progression, unlike Novo Nordisk's semaglutide, which offered no cognitive benefits for early patients.1On December 3, 2025, Biogen CEO Christopher Viehbacher acquired 3,636 shares, increasing his total to 16,443. Some shares were surrendered to cover option costs and taxes.2
- Biogen's Alzheimer's treatments, targeting amyloid deposits, have shown a 30% delay in disease progression, unlike Novo Nordisk's semaglutide, which offered no cognitive benefits for early patients.1
- On December 3, 2025, Biogen CEO Christopher Viehbacher acquired 3,636 shares, increasing his total to 16,443. Some shares were surrendered to cover option costs and taxes.2
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments